↓ Skip to main content

Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy

Overview of attention for article published in EJNMMI Research, October 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

policy
1 policy source

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
74 Mendeley
Title
Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
Published in
EJNMMI Research, October 2016
DOI 10.1186/s13550-016-0233-4
Pubmed ID
Authors

Christina Bluemel, Fraenze Linke, Ken Herrmann, Iva Simunovic, Matthias Eiber, Christian Kestler, Andreas K. Buck, Andreas Schirbel, Thorsten A. Bley, Hans-Juergen Wester, Daniel Vergho, Axel Becker

Abstract

Salvage radiotherapy (SRT) is clinically established in prostate cancer (PC) patients with PSA persistence or biochemical relapse (BCR) after prior radical surgery. PET/CT imaging prior to SRT may be performed to localize disease recurrence. The recently introduced (68)Ga-PSMA outperforms other PET tracers for detection of recurrence and is therefore expected also to impact radiation planning. Forty-five patients with PSA persistence (16 pts) or BCR (29 pts) after prior prostatectomy, scheduled to undergo SRT of the prostate bed, underwent (68)Ga-PSMA PET/CT. The median PSA level was 0.67 ng/ml. The impact of (68)Ga-PSMA PET/CT on the treatment decision was assessed. Patients with oligometastatic (≤5 lesions) PC underwent radiotherapy (RT), with the extent of the RT area and dose escalation being based on PET positivity. Suspicious lesions were detected in 24/45 (53.3 %) patients. In 62.5 % of patients, lesions were only detected by (68)Ga-PSMA PET. Treatment was changed in 19/45 (42.2 %) patients, e.g., extending SRT to metastases (9/19), administering dose escalation in patients with morphological local recurrence (6/19), or replacing SRT by systemic therapy (2/19). 38/45 (84.4 %) followed the treatment recommendation, with data on clinical follow-up being available in 21 patients treated with SRT. All but one showed biochemical response (mean PSA decline 78 ± 19 %) within a mean follow-up of 8.12 ± 5.23 months. (68)Ga-PSMA PET/CT impacts treatment planning in more than 40 % of patients scheduled to undergo SRT. Future prospective studies are needed to confirm this significant therapeutic impact on patients prior to SRT.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 74 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 23%
Student > Master 11 15%
Student > Postgraduate 6 8%
Other 6 8%
Student > Bachelor 5 7%
Other 14 19%
Unknown 15 20%
Readers by discipline Count As %
Medicine and Dentistry 40 54%
Immunology and Microbiology 3 4%
Nursing and Health Professions 2 3%
Agricultural and Biological Sciences 2 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 1%
Other 7 9%
Unknown 19 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2020.
All research outputs
#7,503,741
of 22,925,760 outputs
Outputs from EJNMMI Research
#142
of 558 outputs
Outputs of similar age
#114,353
of 314,181 outputs
Outputs of similar age from EJNMMI Research
#3
of 9 outputs
Altmetric has tracked 22,925,760 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 558 research outputs from this source. They receive a mean Attention Score of 2.5. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,181 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.